Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross, a classic technical signal that often precedes further gains. With momentum traders piling in and Sanofi’s latest Dupixent breakthrough adding serious fuel to the rally, the stock is in ...










